Repro Med Systems Inc (KRMD) — Cash Flow Reinvestment Rate
Repro Med Systems Inc (KRMD) has a Cash Flow Reinvestment Rate of 3.15x as of March 2026, reinvesting $46.16K (capex $46.16K ) from operating cash flow of $14.66K. Explore reinvestment intensity of Repro Med Systems Inc to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Repro Med Systems Inc Cash Flow Reinvestment Rate (1996–2025)
Historical reinvestment intensity for Repro Med Systems Inc across 16 annual periods. Also explore KRMD current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Repro Med Systems Inc (1996–2025)
Year-by-year capital reinvestment analysis for Repro Med Systems Inc. For live market cap and broader valuation context, see Repro Med Systems Inc (KRMD) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 2.02x | $932.52K | $462.40K | $932.52K | ▼ -62.7% |
| 2019 | 5.41x | $1.74 Million | $320.62K | $425.54K | ▲ +262.3% |
| 2018 | 1.49x | $2.21 Million | $1.48 Million | $481.17K | ▲ +512.7% |
| 2017 | 0.24x | $219.47K | $899.91K | $218.33K | ▲ +130.0% |
| 2015 | 0.11x | $203.07K | $1.91 Million | $201.74K | ▼ -88.2% |
| 2014 | 0.90x | $743.78K | $826.10K | $743.78K | ▲ +297.0% |
| 2013 | 0.23x | $216.42K | $954.39K | $216.42K | ▼ -68.6% |
| 2012 | 0.72x | $566.42K | $784.79K | $566.42K | ▲ +71.3% |
| 2011 | 0.42x | $236.24K | $560.60K | $236.24K | ▲ +115.6% |
| 2010 | 0.20x | $200.97K | $1.03 Million | $200.97K | ▲ +33.0% |
| 2009 | 0.15x | $56.16K | $382.30K | $56.16K | ▲ +21.3% |
| 2008 | 0.12x | $63.97K | $528.18K | $63.97K | ▼ -69.2% |
| 2007 | 0.39x | $46.24K | $117.61K | $46.24K | ▼ -69.3% |
| 2002 | 1.28x | $23.47K | $18.32K | $23.47K | ▼ -30.6% |
| 1999 | 1.84x | $177.48K | $96.22K | $177.48K | ▼ -69.3% |
| 1996 | 6.00x | $1.38 Million | $230.00K | $1.38 Million | — |